<DOC>
	<DOCNO>NCT00795353</DOCNO>
	<brief_summary>The study prospective , multi-centre , observational study design ass long-term effectiveness safety alefacept subject moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Assess Long-term Effectiveness Safety Amevive ( Alefacept ) Subjects With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description>Study include bio-marker sub-study determine difference responder vs. non-responders . Additional consent require sub-study .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subjects moderate severe chronic plaque psoriasis receive new prescription alefacept Subjects contraindication alefacept Subjects history cancer except adequately treat basal cell carcinoma ( maximum 2 lesion ) Subjects active cancer , include skin cancer Subjects serious local infection ( eg . cellulitis , abscess ) serious systemic infection ( eg . pneumonia , septicemia , tuberculosis ) , within 3 month prior first dose alefacept . Subjects know infected AIDS virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>alefacept</keyword>
	<keyword>Amevive</keyword>
</DOC>